Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEF1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,058
Award facts
- Contract value 100% obligated
- $49,058.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $49,058.10 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on January 13, 2026, with an ultimate completion date of February 4, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036.
Perjeta is a specialty oncology pharmaceutical used in cancer treatment regimens, reflecting DMS Pharmaceutical Group's established role as a critical supplier of branded and generic pharmaceuticals, biologics, and medical consumables to Department of Defense healthcare facilities worldwide. The delivery order represents one of numerous awards issued to the contractor under the PPV-G GEN V program, positioning the company as a regional prime vendor within the Defense Logistics Agency's broader $30.3 billion pharmaceutical supply chain strategy. As a single-award IDC contractor, DMS Pharmaceutical Group is authorized to fulfill diverse and specialized pharmaceutical requirements supporting military healthcare operations globally, with the firm fixed-price structure ensuring cost predictability for recurring medical supply needs.
Quick answers
Who was awarded contract SPE2DR26FMEF1?
SPE2DR26FMEF1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FMEF1 worth?
The government has obligated $49,058 on SPE2DR26FMEF1.
Is contract SPE2DR26FMEF1 an order under another contract?
Yes. SPE2DR26FMEF1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEF1 competed?
The extent of competition for SPE2DR26FMEF1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award